Boston scientific corporation became aware of the event through the article "unveiling the challenges in tandem ureteral stent management for malignant ureteral obstruction: failure rate, risk factors, and durability of their replacement", orel carmona, asaf shvero, dorit e.Zilberman, zohar a.Dotan, and nir kleinmann.Per the article, 186 patients being treated for malignant ureteral obstruction (muo) received 240 tandem ureteral stent (tus) placements.The patients underwent stenting between 2014 and 2022, then replacement procedures after 12 months.Follow up visits were performed 1 month after stenting then every 2 months thereafter.During the procedures, 2 stents would be placed simultaneously over guidewire under fluoroscopy.The procedures were performed under general anesthesia in the dorsal lithotomy position.In 67 patients, drainage of the stent failed.It was noted that 18 patients experienced sepsis, 3 patients suffered from culture-proven recurrent urinary tract infections leading to recurrent hospitalizations, 33 patients experienced a new finding of hydronephrosis, and 8 patients with acute kidney injury.
|
Block b3: approximated based on the year the first procedures were performed.Block d4, h4: the complainant was unable to provide the suspect device lot number; therefore, the lot expiration and device manufacture dates are unknown.Block e1: initial reporter facility name: (b)(6) hospital.Block g2 (literature source): journal article: orel carmona, et al, 'unveiling the challenges in tandem ureteral stent management for malignant ureteral obstruction: failure rate, risk factors, and durability of their replacement'.J.Clin.Med 2023, 12, 5251.Block h6: imdrf patient codes capture the following reportable events: e0306: sepsis.E1311: unspecified kidney or urinary problem (acute kidney injury).E1906: infection (hydronephrosis).E1310: urinary tract infection.
|